What can I say?
THANK YOU SIR, MAY I HAVE ANOTHER?
Me thinks, Mr. Niedermeyer(that's u stocks:), wil be killed by your own troops(shorts).
We( Bluto Blutarsky's )have nothing to fear.
I’ve read the link, as I’m sure every sucker coyed to their website has.
All I know is an Anthropologist(Robert Proulx), and three restauranteer’s (Friedman, Georgiou, and Theoharis) have roasted retail shareholders along with the remaining geriatric directors(Maslow, Cooper, etc), who have feasted on the votes of their peers.
These guys make isis look nice.
This high tech, cutting edge company has 3 directors who expertise is in the food service industry. I think one of them owns a breakfast/lunch diner, another owns a hot dog stand on Coney Island(seasonal wok), and another owns a canteen truck in Detroit(tough times right now).
Keeps food on the table for Merlin in exchange for shares?
The phase 1 GEN-1 trial for ovarian cancer is posted on the clinicaltrial site, as of 6/23/15. Not yet open for recruitment, but do list estimated completion date in 12/16.
DaVita and FDA warning letter:
Page 34, 4th paragraph from bottom of page, 3rd & 4th sentences; In February 2015, we announced that, in the course of the evaluation, DaVita informed Nephros that they would require additional validation of the system. Nephros and DaVita agreed upon a protocol for the additional validation work which was completed in March. We have submitted the data report to DaVita, and have been informed that it is still under review. Upon confirmatory review of the additional validation work, it is anticipated that DaVita will continue its evaluation.
Page 36, 4th paragraph, last two sentences: We responded to the warning letter within 15 business days as requested by the FDA, and intend to work diligently and expeditiously to resolve the issues raised by the FDA. The warning letter does not restrict the manufacture, production or shipment of any of our products, nor require the withdrawal of any product from the marketplace. (this is also addressed at the top of page 39.
Why Eileen had to refer me to their IR firm to answer those questions is beyond me. After 10+ years, still wonder how this company operates. Don't know why, but I have hope in Director Persen, whose wife didn't offer to sell all like most others.
Was advised to contact Kirin Smith at theie IR firm, PCG Advisory Group, which I did. I left a meaage and Mr. Smith called back promptly to say the Nephros response to the 5/27/15 FDA warning letter was submitted on time.
He could not comment on the DaVita trial due to confidentiality agreements.
No response yet. I will when received.
In the meantime, no one should hesitate to call.
no1, are you able to open " the reduction in erythropoietin(epo) usage" link on their site?
Search" Amgen pimps US senator Baucus for pennies on the dollar".
Also search "members of congress who donated to DaVita".
Then, search "members of congress who donated to Fresenius".
I'm writing one of my congresspeeps, who has first hand experience with kidney disease, and I will include both the Nephros, Inc analysis from the Gambro study(shown on their website), as well as jdbioimed synopsis from renalweb. Will also include our discussion on the value that DSU filters have on reducing tax payer burden of ESA costs and the benefit the DSU filter gives to ERSD patients.
Will also include the pimp article referenced above. Hopefully my peep ain't no pimp. Proof will be in the response.
This is getting fun.
I asked Eileen that question today via email after speaking to her about another issue(I couldn't download the info on their site about"reduction in erythropoietin(epo) usage" located under the DSU tab). She emailed me the epo info that I could not download.
I suggest others try and open that "reduction in erythropoietin(epo) usage" link on their site. I wonder if the problem lies solely with my computer, or if it has been infected by a virus.
The number I have in there DSU revs can't be right. Civil had a good breakdown on that based on 50000 HD machines and 1 filter per year at $300/filter= 15M. Don't know how many HD units are operatin in US, but his # makes more sense.
Colin, I stand corrected, your numbers are correct. The $2100/pt figure represents the actual ESA patient costs of that 6 month study based on jdbiomed numbers. Before incorporating the DSU(Nephros filter), jdbiomed indicates they spend $3500/pt over 6 months, or $7000/patient year on ESA.
B4 DSU, ESA manufacturers USA rev +- $7000/pt X 450000 pts= 3.15B
w DSU, ESA manufacturers USA rev +- $4200/pt X 450000 pts= 1.89B
USA Loss to manufacturers $2800/pt X 450000 pts= $1.26B
max DSU USA revs+- $200/pt x 450000 pts= $90M
So, per jdbiomed(at renalweb post) they spend $4,000 on filters for 20 patients over 6 months. $4,0
00/20 pts yield a filter cost of $200/patient over that time. Assume there is still 6 months more use out of those same filters per Nephros declared usefull life. Filter cost per patient per year = $200/patient year
ESA savings due to filter use of $28,000, representing a 40% cost reduction, over 6 months for those 20 patients. Savings per patient = $28000/20 = $2100/pt per 1/2 year= $4200/patient year
With roughly 450,000 patients on dialysis in the USA, companies like AMGEN stand to "lose" 1.89 Billion in sales of ESA based on American clinics saving $4200 per patient year in ESA costs.
Where'd it go? Merlin loves reubens and shrimp, among other things. It's expensive to eat in New York. Manny has to eat too, not to mention the other hard working directors. Most of it went in the sewer after exiting their digestive tracts, while some went to Schatz
Correction: they have until 6/18/15 to respond. I'm sure Bernie Walsh is drafting the letter in between the horse races.